These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease. Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097 [TBL] [Abstract][Full Text] [Related]
3. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Martinelli P; Contin M; Scaglione C; Riva R; Albani F; Baruzzi A Neurol Sci; 2003 Oct; 24(3):192-3. PubMed ID: 14598082 [TBL] [Abstract][Full Text] [Related]
4. Parkinsonism in the elderly. Hildick-Smith M Curr Med Res Opin; 1982; 7(Suppl 1):14-22. PubMed ID: 7105791 [TBL] [Abstract][Full Text] [Related]
5. Acute stepwise challenge test with levodopa in treated patients with parkinsonism. Feng T; Li W; Lu L; Wang Y; Shi W; Zhang J; Wang Y; Chan P Parkinsonism Relat Disord; 2009 Jun; 15(5):354-8. PubMed ID: 19010079 [TBL] [Abstract][Full Text] [Related]
6. Is levodopa toxic? Fahn S Neurology; 1996 Dec; 47(6 Suppl 3):S184-95. PubMed ID: 8959987 [No Abstract] [Full Text] [Related]
7. [Hypersexuality during use of levodopa]. van Deelen RA; Rommers MK; Eerenberg JG; Egberts AC Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2095-8. PubMed ID: 12448966 [TBL] [Abstract][Full Text] [Related]
8. Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test. Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Meco G Funct Neurol; 2002; 17(4):199-201. PubMed ID: 12675263 [TBL] [Abstract][Full Text] [Related]
9. Parkinson's disease. Clarke CE; Moore AP Am Fam Physician; 2007 Apr; 75(7):1045-8. PubMed ID: 17427619 [No Abstract] [Full Text] [Related]
11. Acute non-haemolytic anemia after short administration of L Dopa plus Benserazide. Pezzoli G; Passerini D; Scarlato G; Radaelli F Ann Allergy; 1982 Jun; 48(6):362. PubMed ID: 7091780 [No Abstract] [Full Text] [Related]
12. Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease. Müller T; Lang UE; Muhlack S; Welnic J; Hellweg R Clin Neuropharmacol; 2005; 28(5):238-40. PubMed ID: 16239764 [TBL] [Abstract][Full Text] [Related]
13. [Benefits of the combination of mucuna, green tea and levodopa/benserazide in Parkinson's disease]. Gonzalez-Maldonado R; Gonzalez-Redondo R; Di Caudo C Rev Neurol; 2016 Jun; 62(11):524-6. PubMed ID: 27222087 [No Abstract] [Full Text] [Related]
14. [Parkinson's disease and pregnancy: case report and literature review]. Routiot T; Lurel S; Denis E; Barbarino-Monnier P J Gynecol Obstet Biol Reprod (Paris); 2000 Sep; 29(5):454-7. PubMed ID: 11011274 [TBL] [Abstract][Full Text] [Related]
15. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Deleu D; Jacob P; Chand P; Sarre S; Colwell A Neurology; 2006 Sep; 67(5):897-9. PubMed ID: 16966563 [TBL] [Abstract][Full Text] [Related]
16. Case report: successful use of rectally administered levodopa-carbidopa. Cooper SD; Ismail HA; Frank C Can Fam Physician; 2001 Jan; 47():112-3. PubMed ID: 11212422 [No Abstract] [Full Text] [Related]